drugset / Trial / NCT00053001
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
Open-labelSupportive care
Summary
RATIONALE: Thalidomide may stop or slow the growth of cancer cells. Epoetin alfa may stimulate red blood cell production. Combining thalidomide with epoetin alfa may improve anemia, decrease the need for blood transfusions, and improve the quality of life in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide with epoetin alfa in treating anemia in patients who have myelodysplastic syndrome.
Timeline
- Start
- 2001-06
- Primary completion
- —
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thalidomide | Other / unclassified | — | Oral |
| Subject | epoetin alfa | Protein / enzyme biologic | — | Subcutaneous |